UMHL yields 1000000.00% · ABBV yields 3.06%● Live data
📍 UMHL pulled ahead of the other in Year 1
Combined, UMHL + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of UMHL + ABBV for your $10,000?
Umatrin Holding Limited, together with its subsidiaries, sells and trades in non-toxic beauty, personal care, health, and wellness products in Malaysia. Its products include Akero Afatelo, a nutrient product which contains telomerase and spirulina; Akero Karela that provides human body with the desired nutrient balance, activate cells, and strengthen the body organs; Unibersih for the treatment of constipation, pigmentation, overweight, bad breath, unsound sleep, lack of physical strength, indigestion, abdominal swelling, dry and pale skin, poor immune system, etc.; Sophielicous, an anti-aging supplement to enhance the longevity of skin cells; and AKERO SECRET, an anti-aging skin care series that include moisturizing cleansing foams, facial toners, brightening serums, soothing emulsions, and ageless and protective sunscreen creams. The company also offers Akero beauty serum to neutralize and repair the effects of emotional and environmental stress on the skin; Resveratrol, a natural antioxidant to reduce blood viscosity, inhibit platelet aggregation and vasodilation, maintain blood flow, and prevent the occurrence and development of various cardiovascular problems; Akero Gold Mask helps to renew skin and improve blood circulation, and is high in antioxidants and minerals; Akero Warming Lipstick; and Akero Feminine Wash, a specially designed sulfate-free intimate wash for a woman's special cleansing needs. It markets its products to retail-based end-users and dealers through an online platform; and a retail shop. The company is based in Kuala Lumpur, Malaysia.
Full UMHL Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.